Diabetes Mellitus in Adults (ADA)

Diabetes Mellitus in Adults (ADA)

AAAAI & ACAAI GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/66809

Contents of this Issue

Navigation

Page 27 of 33

26 Standards of Medical Care Table 14. Noninsulin Therapies for Hyperglycemia in Type 2 Diabetes Properties of selected glucose-lowering drugs that may guide individualization of therapy Class Compound(s) Mechanism Action(s) Advantages Disadvantages Cost Biguanides • Metformin Activate AMP-kinase • Hepatic glucose production ↓ • Intestinal glucose absorption ↓ • Insulin action ↑ • No weight gain • No hypoglycemia • Reduction in CV events and mortality (UKPDS follow-up) • Gastrointestinal (GI) side effects (diarrhea, abdominal cramping ) • Lactic acidosis (rare) • Vitamin B 12 deficiency • Contraindications: reduced kidney function Low Sulfonylureas (SU) (2nd generation) • Glibenclamide/ Glyburide • Glipizide • Gliclazide • Glimepiride Close K ATP channels on β-cell plasma membranes • Insulin secretion ↑ • Generally well tolerated • Reduction in CV events and mortality (UKPDS follow-up) • Relatively glucose-independent stimulation of insulin secretion: Hypoglycemia, including episodes necessitating hospital admission and causing death • Weight gain • May blunt myocardial ischemic preconditioning • Low "durability" Low Meglitinides • Repaglinide • Nateglinide Close K ATP channels on β-cell plasma membranes • Insulin secretion ↑ • Accentuated effects around meal ingestion • Hypoglycemia, weight gain • May blunt myocardial ischemic preconditioning • Frequent dosing schedule Medium iazolidinediones (glitazones) • Pioglitazone Activate the nuclear tran- scription factor PPAR-γ • Peripheral insulin sensitivity ↑ • No hypoglycemia • HDL-C ↑ • Triglycerides ↓ • Weight gain • Edema • Heart failure • Bone fractures High • Rosiglitazone As above • As above • No hypoglycemia • LDL-C ↑ • Weight gain • Edema • Heart failure • Bone fractures • Increased CV events (mixed evidence) • FDA warnings on CV safety • Contraindicated in patients with heart disease High α-Glucosidase inhibitors • Acarbose • Miglitol Inhibit intestinal α-glucosidase • Intestinal carbohydrate digestion (and, consecutively, absorption) slowed • Nonsystemic medication • PPG ↓ • GI side effects (gas, flatulence, diarrhea) • Frequent dosing schedule Medium

Articles in this issue

Archives of this issue

view archives of Diabetes Mellitus in Adults (ADA) - Diabetes Mellitus in Adults (ADA)